AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
|Articles|August 23, 2012
BREAKING: CMS Issues Final Rule for Stage 2 of EHR Incentive Program
Advertisement
The CMS issued the final requirements that hospitals and other providers must meet to receive funding under the second phase of the federal electronic health-record incentive program.
The Stage 2 meaningful-use requirements that providers must satisfy to receive payments under the program will go into effect in early 2014, according to a
Read the full story:
Source: ModernHealthcare.com
Advertisement
Related to this article
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
3
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5